High-throughput Screening Market Outlook 2031
The global high-throughput screening market size was USD 23.03 Billion in 2022 and is anticipated to reach USD 61.84 Billion by 2031 expand at a CAGR of 11.6% during the forecast period, 2023– 2031. The growth of the market is attributed to increasing technological advancements in the drug discovery techniques using 3D-cell cultures.
High-throughput screening (HTS) is a method used in drug discovery and in the field of biology and chemistry. It allows automated testing of large numbers of chemical and/or biological compounds for a specific biological target. This method is used in the pharmaceutical industry. It leverages robotics and automation to quickly test the biological or biochemical activity of a large number of molecules, drugs.
HTS accelerate target analysis, as large-scale compound libraries can quickly screen in a cost-effective manner. It assesses pharmacological targets and enzymes and rapidly identify active compounds, antibodies, or genes that modulate a biomolecular pathway.
The primary goal of HTS is to identify compound library screenings and candidates that affect the target. It is achieved by employing liquid handling devices, robotics, plate readers as detectors and dedicated software for instrumentation control and data processing. The results of HTS assays provide the starting point in the drug discovery pipeline, which includes drug design and helps in understanding the interaction or role of a particular biochemical process.
High-throughput Screening Market Trends, Drivers, Restraints, and Opportunities:
- Rising R&D investments and increasing government funding & venture capital investments are expected to positively impact the market growth.
- Increasing number of pharmaceutical companies and rising demand for drugs owing to growing prevalence of diseases are anticipated to propel the growth of the market.
- Growing numerous complexities in the field of assay development & target identification can hinder the market growth.
- Contract research organizations (CROs) offer drug discovery services to pharmaceutical & biotechnology companies. Thus, rising number of CROs can create lucrative opportunities for the market growth.
Scope of The High-throughput Screening Market Report
The report on the global high-throughput screening market research report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
High-throughput screening - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Technologies (Ultra-high-throughput Screening, Cell-based Assays, Lab-on-a-chip, and Label-free Technology), Applications (Target Identification, Primary Screening, and Toxicology), Products and Services (Instruments, Reagent and Kits, and Services), End-Users (Pharmaceutical and Biotechnology Firms, Academia and Research Institutes, and Contract Research Organizations)
North America, Europe, South America, Asia Pacific, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., and Thermo Fisher Scientific Inc.
Global High-throughput screening Market Segment Insights
Cell-based assays segment to account a major market share
Based on technologies, the market is divided into ultra-high-throughput screening, cell-based assays, lab-on-a-chip and label-free technology. The cell-based assays segment accounted for more than 55% of the market share in 2020, in terms of revenue. This is anticipated to continue to account for a major market share during the forecast period.
Fluorometric imaging plate reader assays is the most used cell-based assays due to visible results and their ability to test with the smallest of volumes. Ultra high-throughput screening is the latest technology adopted in the market. This segment is excepted to hold a significant market share during the forecast period.
Pharmaceutical and biotechnology firms segment to account a considerable market share
Based on end-users, the market is segmented into pharmaceutical and biotechnology firms, academia and research institutes, contract research organisations. The pharmaceutical and biotechnology firms segment to account for a considerable market share owing to growing focusing on the development of novel molecules for the treatment of several chronic conditions.
Increasing requirement for rapid and precise screening of several target molecules during drug discovery and development phases has led to the adoption of automated high-throughput screening techniques to screen massive chemical and biomarker libraries generated during the research processes is expected to boost the market segment.
Reagent and kits segment to account a major share
Based on products and services, the market is segmented into instruments, reagent and kits, and services. The reagent and kits segment accounted for a major share of the global high-throughput screening market in 2020, in terms of revenue. Wide range of reagents & assay kits used in HTS techniques, rising pharmaceutical R&D activities, and increasing government funding for life sciences research are driving the growth of the market segment.
North America to dominate the Market
In terms of regions, the market is segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is anticipated to dominate the market owing to the high adoption rate of HTS in the US. The growth of the US high-throughput screening market is attributed to the significant advancements in combinatorial chemistry and the field of genomics. Moreover, huge investments by the pharmaceutical industry for HTS technologies is expected to propel the regional market growth.
The global high-throughput screening market has been segmented on the basis of
- Ultra-high-throughput Screening
- Cell-based Assays
- Label-free Technology
- Target Identification
- Primary Screening
Products and Services
- Reagent and kits
- Pharmaceutical and Biotechnology Firms
- Academia and research institutes
- Contract Research Organisations
- North America
- Asia Pacific
- Latin America
- Middle East & Africa
Key players operating in the market includes Agilent Technologies Inc., Bio-Rad Laboratories Inc., Merck KGaA, PerkinElmer Inc., Thermo Fisher Scientific Inc.